gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BIOAHealthcarePharmaceuticals

BioAge Labs, Inc. Common Stock (BIOA)

$5.95−0.17%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$5.95▼ 20.35% in range
Nov 4, 2025Low $4.84 · High $25.10Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

BioAge Labs closed at $5.95 on Nov 4, down 0.17%, 76.3% below its 52-week closing high. Volume of 613.1K shares was 0.76× its 20-day average (below normal).

Split-adjusted performance: -5.4% over one month, -67.8% over six months, -19.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $2.45M, up 1.6% from a year earlier, with a net margin of -1064.7%.

Short interest was 3.4M shares at the Oct 15 settlement, up 4.8% from the prior report (12.0% of float, 3.7 days to cover).

Market cap$273.1M45.9M shares
Revenue · quarter$2.5M+1.6% YoY
Diluted EPS$-0.58—
P/E · TTM—P/S 26.4×
Net margin-1,064.7%Gross 100.0%
Dividend yieldNone
52-week range4.84 – 25.10−76.3% from high
Volume613.1K0.76× 20-day avg
Volatility · 60d66.2%Annualised
Short % of float12.0%3.7 days to cover
Net cash$318.7MCash $318.7M
Next earnings—Not scheduled
Split-adjusted performance
1W +0.2%1M −5.4%3M −47.2%6M −67.8%YTD −55.0%1Y −19.8%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum13
Revenue growth43
Net margin21
Value (low P/E)—
Size52

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short3.4M+4.8% vs prior
Days to cover3.7Settled Oct 15
% of float12.0%
Short vol. 10d43.5%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BIOABioAge Labs$5.95−0.17%−67.8%+1.6%−1064.7%—$273.1M
QTTBQ32 Bio$8.97+2.40%+64.0%——7.9$267.0MCompare
USNAUSANA Health Sciences$14.33−3.63%−28.4%−5.3%−9.6%—$264.8MCompare
RCKTRocket Pharmaceuticals$2.61+3.98%−32.4%———$286.5MCompare
LRMRLarimar Therapeutics$2.76+8.66%−33.5%———$286.7MCompare
FULCFulcrum Therapeutics$3.77+0.80%−47.0%———$288.0MCompare
VOGXVogenx$19.73−3.90%————$293.1MCompare
TTRXTurn Therapeutics$9.80+3.05%+158.2%———$297.6MCompare
EBSEmergent Biosolutions$5.90−5.60%−35.2%−52.4%−29.7%—$302.5MCompare

News about BioAge Labs

All news →
BioAge Labs to Present at Upcoming Investor ConferencesGlobeNewswire Inc. · Sep 2, 2026▲ PositiveBioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire Inc. · Aug 5, 2026▲ PositiveBioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular RiskGlobeNewswire Inc. · Jun 16, 2026▲ PositiveBioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRPGlobeNewswire Inc. · Apr 21, 2026▲ Positive

Quick answers

What does BioAge Labs do?
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging.
What is BIOA's market cap?
$273.09M, based on the Nov 4 close of $5.95.
Does BioAge Labs pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BIOA is sold short?
3.4M shares, 12.0% of float, as of Oct 15, 2026.
What sector is BIOA in?
Healthcare, in the Pharmaceuticals industry.

About BioAge Labs

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

HQ: Emeryville, CA62 employeesListed Sep 26, 2024bioagelabs.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology